Clinical applications of FDG-PET in oncology.
Positron emission tomography together with F-18-deoxyglucose (FDG) has emerged as a valuable clinical tool in the field of oncology. FDG-PET diagnoses, stages and restages most cancers with a high diagnostic accuracy. The effects of chemotherapy on tumour metabolism can be monitored with this whole-body technique. Recent studies have established a high prognostic accuracy of PET for predicting the clinical outcome of cancer patients. The current review addresses the role of FDG-PET for diagnosing, staging and restaging of lung cancer, colorectal cancer, lymphoma, melanoma and breast cancer staging and provides a brief outlook for future applications of clinical PET imaging.
Czernin
J
J
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic, UCLA School of Medicine, Los Angeles, California, USA. jczernin@mednet.ucla.edu
D019788:Fluorodeoxyglucose F18; D006801:Humans; D009362:Neoplasm Metastasis / Q000000981:diagnostic imaging; D009367:Neoplasm Staging; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed / Q000379:methods*
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18